On Nov. 5, the American Lung Association in Florida released the 2025 “State of Lung Cancer” report...
Join our family of readers for as little as $10 per month and support local, unbiased journalism.
Already have an account? Log in to continue. Otherwise, follow the link below to join.
Please log in to continue |
MIAMI – On Nov. 5, the American Lung Association in Florida released the 2025 “State of Lung Cancer” report, which reveals that more needs to be done to end the burden of this devastating disease on families throughout the state. Lung cancer is the leading cause of cancer deaths here in Florida and across the U.S. The report finds Florida ranks 45th out of 49 in the nation for lung cancer cases not being treated.
The Lung Association’s eighth annual “State of Lung Cancer” report highlights how the toll of lung cancer varies by state and examines key indicators throughout the U.S., including new cases, survival, early diagnosis, surgical treatment, lack of treatment, screening rates and insurance coverage of comprehensive biomarker testing.
The report found that Florida ranks:
• 22 out of 51 in the nation for rate of new lung cancer cases, at 53.60 per 100,000. The national rate is 52.8 per 100,000.
• 42 out of 50 in the nation for early diagnosis, at 26%. Nationally, only 28.1% of cases are diagnosed at an early stage when the survival rate is much higher.
“In the last decade, we have seen incredible progress, including increases in lung cancer survival and early detection rates across the nation,” said Ashley Lyerly, senior director of advocacy for the American Lung Association. “While this progress gives us hope, Florida still has higher than the average rate of residents diagnosed with lung cancer who are seeking no treatment. Working to increase awareness and access to lung cancer screening while also ensuring coverage of comprehensive biomarker testing for all insurance plans is critical to saving lives. The state must step in to ensure residents across Florida have access to the best lung cancer care.”
The “State of Lung Cancer” report also examines insurance coverage of comprehensive biomarker testing across the U.S. Lung cancer biomarker testing, sometimes referred to as tumor, molecular, genomic or genetic testing, looks for changes in the tumor’s DNA. The results of the test may show biomarkers that can help determine what treatment options would be best for an individual patient. Insurance coverage of biomarker testing is important for removing a cost barrier to people with lung cancer, but coverage for biomarker testing is only required in some states. The report found that Florida requires coverage of biomarker testing, but only in some health plans.
The 2025 “State of Lung Cancer” report highlights opportunities for states to reduce the burden of lung cancer and encourages everyone to help end lung cancer. This year, the American Lung Association calls for the state to implement policies to require insurance coverage of comprehensive biomarker testing. Learn more about the report and take action at Lung.org/solc.
Get involved and help the mission of the American Lung Association. The Fight For Air Climb in Miami is coming up on March 1, 2026. Learn more at FightForAirClimb.org/Miami.